Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

COVID-19 2Severe Acute Respiratory Syndrome 1Papillomavirus Infections 1Multiple Myeloma 1Mastocytosis 1Lymphoma 1Leukemia 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 30Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 20Papillomavirus Vaccines 9Radiotherapy, Intensity-Modulated 4Cisplatin 4Blood Specimen Collection 4fludarabine 3Vaccines, Synthetic 3Engerix-B 3Cyclophosphamide 3halofantrine 2fludarabine phosphate 2aldesleukin 2Watchful Waiting 2Vaccines 2Patient Navigation 2Paclitaxel 2Light Coagulation 2Interleukin-2 2Imiquimod 2Human Papillomavirus Recombinant Vaccine nonavalent 2Hepatitis A Vaccines 2Fluorouracil 2Electrocoagulation 2Cetuximab 2Carboplatin 2Albumin-Bound Paclitaxel 2utomilumab 1polyphenon E 1infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Papillomavirus Infections × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡